🔴 Damora Therapeutics is trading 8.6% down in pre-market after quarterly net loss widened to $31.2 million

Damora Therapeutics is trading at $27.00 (-8.6%) after second-quarter results reported on August 10, 2026.

• Q2 EPS of -$0.39 beat the -$0.43 consensus estimate, but quarterly net loss widened to $31.2 million as research spending increased.
• The company-specific earnings reaction outweighs modestly positive broader-market futures.